Oncology Community Sees Potential for Patient Harm in FDA OK of 23andMe BRCA Test

Mar 07, 2018

|

Premium

NEW YORK (GenomeWeb) – Since 2013, when 23andMe had to stop marketing health-related test reports due to regulatory action from the US Food and Drug Administration, the consumer genomics firm has detected but not reported one of three specific mutations in the BRCA1 and BRCA2 genes in nearly 3,000 of its customers.

These individuals can now decide if they wish to find out their status for these BRCA1/2 mutations after 23andme this week won FDA authorization to report the test results directly to consumers (DTC).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Breaking News

The Scan

Hundreds of Thousands Wasted

The Associated Press reports that the US government wasted $341,000 on travel by former Health and Human Services Secretary Tom Price.

Down in the Comments

Women who post YouTube science videos get more critical comments and more comments about their appearance than male video hosts, the New York Times reports.

Mistrust Lingers

The Wall Street Journal writes that participating in genetic research brings up the specter of past research ethics lapses for some African Americans.

This Week in PLOS

In PLOS this week: sequences influencing yeast prion aggregation or degradation, dengue virus genetic variants affect transmission dynamics, and more.

Featured White Papers

Application of the Megaruptor for Shearing of Ultra-Long DNA Fragments in the Context of Long Read Sequencing using Third-Gen Sequencing Technologies

Megaruptor Genomic DNA Shearing for Large Insert Sequencing Library Preparation

Discovering Neuronal Cell Types

Immuno-Oncology: 3 Strategies for Applying Humanized Models

Jul

19

Featured Webinar

Advances in NGS for Ultra-High Sensitivity Applications in Translational and Clinical Research

This webinar will discuss how ultra-highly sensitive and customizable targeted next-generation sequencing panels are applied in inherited disease research.

Jul

24

Featured Webinar

Identifying Inherited Risk Factors of Pancreatic Cancer Using Targeted Sequencing in a Large Cohort

In this webinar, Dr. Fergus Couch from the Mayo Clinic will present data from a large study that used a targeted sequencing panel to determine pancreatic cancer risk associated with inherited mutations in several cancer predisposition genes.

Jul

25

Featured Webinar

Antibiotic Gene Surveillance: What You Don’t See Can Hurt You!

This online seminar will discuss the advantages of incorporating molecular testing into the microbiology laboratory to aid in the identification of relevant antibiotic resistance mechanisms.

Aug

09

Featured Webinar

Analytical Utility of Mass-Spec Liquid Biopsy for NSCLC and Melanoma Samples

In this two-part webinar, Dr. Elin Gray, from Edith Cowan University, and Ms. Weiwei Zhao, from Kingmed diagnostic, will compare the highly sensitive, multiplexed UltraSEEK technology, on the MassARRAY system, to digital droplet PCR (ddPCR) results on melanoma and non-small cell lung carcinoma samples.

Main menu